Relapsed or Refractory Hematologic Malignancies
·MeSH: Recurrence
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
Phase 1(1)
| Drug | Company |
|---|---|
| tti-621 | Trillium Therapeutics Inc. (TRIL) |
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed or Refractory Hematologic Malignancies?
BioSniper tracks 2 drugs in development for Relapsed or Refractory Hematologic Malignancies across 2 companies.
How many clinical trials target Relapsed or Refractory Hematologic Malignancies?
There are 1 clinical trial targeting Relapsed or Refractory Hematologic Malignancies tracked by BioSniper.
Deep-dive into Relapsed or Refractory Hematologic Malignancies
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis